Drug intelligence / Profile preview

AGN-207281

Development stage: Phase 1
Lead developer: Allergan
Modality: Small Molecules
Administration: Ophthalmic

Overview

AGN-207281 is a small molecule drug developed for ophthalmic use, specifically as an investigational treatment for eye diseases such as ocular hypertension and primary open-angle glaucoma. It was designed to interact with specific biological targets to modulate intraocular pressure, though the precise molecular target and mechanism of action have not been publicly disclosed. The drug has undergone early-phase clinical evaluation in comparison with timolol ophthalmic solution and placebo in patients with ocular hypertension or primary open-angle glaucoma[1][2][3]. Development was led by Allergan.

Beyond the preview

Go deeper on AGN-207281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGN-207281.

Explore the full profile